Utilization of biologic disease-modifying antirheumatic drugs for plaque psoriasis

Record ID 32018002261
Authors' objectives: Plaque psoriasis (PsO) is an inflammatory condition characterized by inflamed scaly patches of skin all over the body and is associated with lowered quality of life and serious comorbidities. Several biologics for the treatment of PsO have been reimbursed in Canada in the past decade, spanning different mechanisms of action and annual costs. Many of these biologics have expired data exclusivity status. Following the Environmental Scan for biologics in PsO (ES0357), a utilization study is warranted to study the patterns of use of these biologics across public drug plans to support potential formulary management discussions. This analysis will collect claims data for biologics across public drug plans from the past several years. Market shares and opportunity costs of delayed biosimilar uptake for drugs with expired exclusivity status will be evaluated.
Project Status: Ongoing
Anticipated Publish Date: 2022
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Canada
MeSH Terms
  • Psoriasis
  • Drug Therapy
  • Etanercept
  • Tumor Necrosis Factor-alpha
  • Immunosuppressive Agents
  • Molecular Targeted Therapy
  • Adalimumab
  • Infliximab
  • Certolizumab Pegol
  • Ustekinumab
  • Biological Products
  • Plaque psoriasis
  • Biologics
  • Disease-modifying antirheumatic drugs
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca

Canadian Agency for Drugs and Technologies in Health (CADTH)

This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.